augustine chen - Genetic Mutations

Author Information

Augustine Chen is affiliated with the Cancer Genetics Laboratory at the Centre for Translational Cancer Research (Te Aho Matatū), Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand. His research primarily focuses on cancer genetics, synthetic lethal approaches, and protein production. Augustine has made significant contributions to understanding the vulnerabilities in cancer cells, particularly those deficient in E-cadherin.

Research Contributions

Augustine Chen has extensively studied synthetic lethal vulnerabilities in cancer cells, particularly focusing on E-cadherin-deficient cells. His work has led to the identification of novel synthetic lethal compounds and allosteric AKT inhibitors that target these specific cancer cell vulnerabilities. Additionally, he has contributed to the field of protein production by exploring how synonymous codon changes at translation initiation sites can tune protein yield. His research also extends to the application of fused organoid models to study human brain development and neural disorders.

Aliases

Augustine Chen is also known by the alias "Augustin Chen."

Publication and Citation Metrics

Metric	Value
Total Papers	19
Citation Count	438
H-index	11

Publications:

Analysis of 11,430 recombinant protein production experiments reveals that protein yield is tunable by synonymous codon changes of translation initiation sites

DOI: 10.1371/journal.pcbi.1009461

Year: 2021

Application of Fused Organoid Models to Study Human Brain Development and Neural Disorders

DOI: 10.3389/fncel.2020.00133

Year: 2020

Protein yield is tunable by synonymous codon changes of translation initiation sites

DOI: 10.1101/726752

Year: 2019

A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells

DOI: 10.1038/s41598-019-48929-0

Year: 2019

Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells

DOI: 10.3390/cancers11091359

Year: 2019

E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function

DOI: 10.1007/s10120-018-0859-1

Year: 2018

Abstract B04: Synthetic lethal targeting of E-cadherin-deficient cancers

DOI: 10.1158/1557-3265.PMCCAVULN16-B04

Year: 2017

Abstract B41: Statins show synthetic lethality in E-cadherin-deficient cells and are synergistic with SRC and HDAC inhibitors

DOI: 10.1158/1557-3265.PMCCAVULN16-B41

Year: 2017

Abstract 3814: Synthetic lethal approaches targeting E-cadherin-deficient cancers

DOI: 10.1158/1538-7445.AM2016-3814

Year: 2016

Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells

DOI: 10.1158/1535-7163.MCT-14-1092

Year: 2015

How Common are BRCA1 and BRCA2 Mutations?

What Are the Applications of Sanger Sequencing in Genetic Research?

How Do Mutations Contribute to Evolution?

How Does UV Radiation Cause Genetic Mutations?

Are There Potential Treatments Targeting Genetic Mutations?

How Does Hydroxyurea Affect Genetic Mutations?

What are Immunotherapies?

What is Sanger Sequencing?

How does Research Advance Treatment?

How Do Genetic Mutations Affect Fertility?

Partnered Content Networks

Relevant Topics